ACMT Position Statement: Position on the Recent Judicial Challenge of U.S. Food and Drug Administration Approval of Mifepristone
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Journal of medical toxicology - 19(2023), 4 vom: 07. Aug., Seite 414-415 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mazer-Amirshahi, Maryann [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
|---|
| Anmerkungen: |
© American College of Medical Toxicology 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s13181-023-00960-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR05321191X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR05321191X | ||
| 003 | DE-627 | ||
| 005 | 20231002145600.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231002s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s13181-023-00960-4 |2 doi | |
| 035 | |a (DE-627)SPR05321191X | ||
| 035 | |a (SPR)s13181-023-00960-4-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mazer-Amirshahi, Maryann |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a ACMT Position Statement: Position on the Recent Judicial Challenge of U.S. Food and Drug Administration Approval of Mifepristone |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © American College of Medical Toxicology 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 650 | 4 | |a Drug safety |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a FDA |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Mifepristone |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Toxicology |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Pregnancy |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Stolbach, Andrew I. |4 aut | |
| 700 | 1 | |a Ye, Peggy |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of medical toxicology |d New York, NY : Springer, 2005 |g 19(2023), 4 vom: 07. Aug., Seite 414-415 |w (DE-627)SPR030753856 |w (DE-600)2405491-4 |x 1937-6995 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2023 |g number:4 |g day:07 |g month:08 |g pages:414-415 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s13181-023-00960-4 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2023 |e 4 |b 07 |c 08 |h 414-415 | ||